Chronic Heart Failure Forecasts to 2028: Quantify Patient Populations in the Global Chronic Heart Failure Market to Target the Development of Future Products, Pricing Strategies and Launch Plans

News provided by

Research and Markets

18 Dec, 2017, 11:00 GMT

DUBLIN, Dec. 18, 2017 /PRNewswire/ --

The "Chronic Heart Failure Forecast in 12 Major Markets 2018-2028" report has been added to Research and Markets' offering.

Chronic heart failure (CHF) is a chronic disease during which the heart is not able to supply sufficient blood flow to the body. Exacerbations of CHF are characterised by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs. The disease is associated with toxic, inflammatory and infective heart damage, structural, metabolic and genetic heart abnormalities, as well as cardiovascular risk factors, such as smoking, sedentary lifestyle, unhealthy diet and alcohol consumption.

This report provides the current prevalent population for chronic heart failure across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, Brazil & India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, patient populations with the two types of chronic heart failure, as well as several of the main symptoms and co-morbidities of chronic heart failure have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for chronic heart failure include:

  • Arterial hypertension
  • Coronary artery disease
  • Atrial fibrillation
  • Diabetes mellitus
  • Metabolic syndrome
  • Obesity
  • Renal dysfunction
  • Chronic obstructive pulmonary disease (COPD)
  • Pulmonary hypertension
  • Sleep apnoea
  • Anaemia

Key Topics Covered:

  1. Introduction
  2. Cause of the Disease
  3. Risk Factors & Prevention
  4. Diagnosis of the Disease
  5. Variation by Geography/Ethnicity
  6. Disease Prognosis & Clinical Course
  7. Key Comorbid Conditions / Features Associated With the Disease
  8. Methodology for Quantification of Patient Numbers
  9. Top-Line Prevalence for Chronic Heart Failure
  10. Chronic Heart Failure With Reduced Ejection Fraction
  11. Features of Chf-Ref Patients
  12. Comorbid Conditions of Chf-Ref Patients
  13. Chronic Heart Failure With Preserved Ejection Fraction
  14. Features of Chf-Pef Patients
  15. Comorbid Conditions of Chf-Pef Patients
  16. Abbreviations Used in the Report
  17. Other Publications
  18. Online Patient-Based Databases
  19. Patient-Based Offering
  20. Online Pricing Data & Platforms
  21. References
  22. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/tcb6pb/chronic_heart?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com